Sitagliptin With Pembro in RCC and Melanoma

Sponsor
Fernando Maciel Barbosa
Study ID
NCT07634380
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Melanoma
  • Advanced Renal Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Sitagliptin — DRUG
    An oral dipeptidyl peptidase-4 (DPP-4) inhibitor administered once daily at escalating dose levels adjusted for renal function, used to evaluate safety and potential immunomodulatory and anti-tumor activity in combination with pembrolizumab
  • Pembrolizumab — DRUG
    A programmed death-1 (PD-1) immune checkpoint inhibitor administered as a 200 mg intravenous infusion every 3 weeks, used as standard-of-care immunotherapy in advanced melanoma and renal cell carcinoma

Study Details

This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped responding to prior PD-1 or PD-L1 immunotherapy. The study has two parts. In the first part, small groups of participants will receive different doses of sitagliptin along with a fixed dose of pembrolizumab. This helps researchers find the highest dose of sitagliptin that can be given safely. In the second part, more participants will receive the safest dose to see how well the drug combination works against their cancer.

Key Dates

Start date
May 15, 2026
Status verified
Feb 2026
Primary completion
Apr 10, 2028
Completion
Apr 10, 2031

Study Design

Enrollment
64 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Sitagliptin + Pembrolizumab Combination Therapy (aRCC)
    Participants with refractory or relapsed advanced renal cell carcinoma will receive oral sitagliptin administered daily at escalating dose levels (adjusted by renal function) in combination with fixed-dose pembrolizumab 200 mg IV every 3 weeks. The arm includes a dose-escalation phase to determine the maximum tolerated dose (MTD) of sitagliptin followed by a dose-expansion phase to evaluate preliminary efficacy and safety at the MTD.
  • Experimental: Sitagliptin + Pembrolizumab Combination Therapy (aM)
    Participants with refractory or relapsed advanced melanoma will receive oral sitagliptin administered daily at escalating dose levels (adjusted by renal function) in combination with fixed-dose pembrolizumab 200 mg IV every 3 weeks. This arm similarly includes a dose-escalation phase to determine the MTD of sitagliptin followed by a dose-expansion phase to assess preliminary efficacy and safety at the MTD.

Primary Outcome Measure

Dose-Limiting Toxicities (DLTs) [ Time Frame: During cycle 1 (cycle 1 is 21 days) ]

Central Contacts

Related Studies